Blog & Resources Camargo Blog April 16th, 2008

NanoNews—Beads Deliver Drug to Site of Action

In another fine example of a formulation change, Biocompatibles International reported that its very small beads were used to sequester Doxorubicin (adriamycin). The resulting beads were delivered via a catheter directly into the liver of patients with liver tumors. The tumor growth was suppressed for long enough in 12 of 18 patients to receive a transplant.

We have previously reported the use of a special carbohydrate that sequesters a tumor fighting agent and delivers the drug directly to the tumor (click thumbnail below to enlarge).

These examples show the use of novel excipients in conjunction with previously approved drugs – a classic 505(b)(2) drug product.

Categories: 505(b)(2) Development / CMC

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights